SCHEMBL964809

SCHEMBL964809

CCCCNS(=O)(=O)NC(=O)/C=C/c1c(C)nn(C)c1-c1cn(C)c2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.40
HDAC2 Q92769 6/20 0.40
HDAC6 Q9UBN7 6/20 0.40
HDAC3 O15379 5/20 0.40
HDAC4 P56524 5/20 0.40
HDAC7 Q8WUI4 5/20 0.40
HDAC8 Q9BY41 5/20 0.40
HDAC9 Q9UKV0 5/20 0.40
HDAC5 Q9UQL6 5/20 0.40
HDAC10 Q969S8 4/20 0.40
HDAC11 Q96DB2 4/20 0.40
POLB P06746 1/20 0.35
CASP6 P55212 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
THRB P10828 1/20 0.34
EGFR P00533 2/20 0.34
GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964810 1.00 HDAC1 (0.40) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL964243 0.87 PPARG (0.39) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL964240 0.87 PPARG (0.39) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL28785088 0.85 HDAC1 (0.35) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL966139 0.81 POLB (0.36) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL966137 0.81 POLB (0.36) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL964902 0.80 HDAC3 (0.35) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL964903 0.80 HDAC3 (0.35) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL963892 0.79 POLB (0.35) HDAC1HDAC2HDAC6HDAC3HDAC4
SCHEMBL963893 0.79 POLB (0.35) HDAC1HDAC2HDAC6HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 HDAC1 108/4885HDAC2 333/4885HDAC6 355/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG HDAC1 338/4885HDAC2 845/4885HDAC6 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.